GlassScriptPhysician profile
Seetharaman Adimoolam
NPI 1447336755
$1,045.83
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $53.19 · 2021: $289 · 2022: $261.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $424.98 | 2019-2022 | |
| Amgen INC. | $244.18 | 2021-2022 | |
| Shire North American Group INC | $170.51 | 2019 | |
| Csl Behring | $109.54 | 2019 | |
| Glaxosmithkline, LLC. | $41.71 | 2019-2020 | |
| Circassia INC. | $21.80 | 2019 | |
| Aimmune Therapeutics, INC. | $16.67 | 2021 | |
| Alk-Abello, INC | $16.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seetharaman Adimoolam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.